Cargando…

Antithrombotic Therapy in Cardiac Embolism

Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Cervera, Álvaro, Chamorro, Ángel
Formato: Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994115/
https://www.ncbi.nlm.nih.gov/pubmed/21804782
http://dx.doi.org/10.2174/157340310791658749
_version_ 1782192886500032512
author Cervera, Álvaro
Chamorro, Ángel
author_facet Cervera, Álvaro
Chamorro, Ángel
author_sort Cervera, Álvaro
collection PubMed
description Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a better outcome mediated in part by its anti-inflammatory properties.
format Text
id pubmed-2994115
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Bentham Science Publishers Ltd.
record_format MEDLINE/PubMed
spelling pubmed-29941152011-08-01 Antithrombotic Therapy in Cardiac Embolism Cervera, Álvaro Chamorro, Ángel Curr Cardiol Rev Article Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a better outcome mediated in part by its anti-inflammatory properties. Bentham Science Publishers Ltd. 2010-08 /pmc/articles/PMC2994115/ /pubmed/21804782 http://dx.doi.org/10.2174/157340310791658749 Text en © 2010 Bentham Science Publishers Ltd. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Cervera, Álvaro
Chamorro, Ángel
Antithrombotic Therapy in Cardiac Embolism
title Antithrombotic Therapy in Cardiac Embolism
title_full Antithrombotic Therapy in Cardiac Embolism
title_fullStr Antithrombotic Therapy in Cardiac Embolism
title_full_unstemmed Antithrombotic Therapy in Cardiac Embolism
title_short Antithrombotic Therapy in Cardiac Embolism
title_sort antithrombotic therapy in cardiac embolism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994115/
https://www.ncbi.nlm.nih.gov/pubmed/21804782
http://dx.doi.org/10.2174/157340310791658749
work_keys_str_mv AT cerveraalvaro antithrombotictherapyincardiacembolism
AT chamorroangel antithrombotictherapyincardiacembolism